Welcome to our dedicated page for MediWound Ltd. news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on MediWound Ltd. stock.
MediWound Ltd. (Nasdaq: MDWD) is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products. The company's mission is to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other medical conditions. MediWound leverages its patented proteolytic enzyme technology to create innovative and effective treatments.
NexoBrid®, MediWound's flagship product, has received marketing authorization from multiple health agencies, including the European Medicines Agency, as well as health ministries in Israel and Argentina. This innovative biopharmaceutical product is designed for the non-surgical removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns. Clinical trials have demonstrated NexoBrid's capability to rapidly and effectively debride eschar without harming viable tissue.
MediWound's pipeline includes several promising products. EscharEx®, another key product, is a topical biological drug being developed for debridement of chronic wounds. This product has shown significant potential in clinical trials, suggesting it can outperform traditional enzymatic debridement methods and improve patient outcomes. Additionally, MW005 is under development for the treatment of non-melanoma skin cancers, offering a new hope for patients with basal cell carcinoma.
The company has established valuable partnerships and research collaborations with industry leaders such as 3M, Mölnlycke, and MIMEDX. These collaborations aim to further validate and enhance MediWound's product pipeline. Recent achievements include substantial governmental grants, expanded indications for NexoBrid, and successful market entries in new regions.
Financially, MediWound is on solid ground. As of December 31, 2023, the company reported a cash, restricted cash, and investments balance of $42.1 million, compared to $34.1 million at the end of 2022. In the first quarter of 2023, MediWound raised $27.5 million through a registered direct offering, using $17.1 million to support its activities. The company expects its existing financial resources to be sufficient to reach profitability.
MediWound's commitment to improving patient care through innovative enzymatic therapeutics positions it as a significant player in the biopharmaceutical industry. With a strong pipeline and robust financial health, the company aims to continue delivering life-saving treatments and expanding its market presence.
For more information, visit www.mediwound.com and follow the company on LinkedIn and X.
MediWound Ltd. (Nasdaq: MDWD) will announce its second-quarter financial results for the period ending June 30, 2022, on August 9, 2022, at 8:30 AM ET. Following the announcement, a conference call will be held to discuss these results and provide corporate updates. The company focuses on developing biotherapeutic solutions for tissue repair, including NexoBrid for burn care and EscharEx for chronic wound debridement. The upcoming call will allow investors to gain insights into financial performance and business operations.
MediWound Ltd. (Nasdaq: MDWD) announced positive initial results from its Phase I/II study of MW005 for low-risk Basal Cell Carcinoma (BCC). The data indicates that MW005 is safe, well-tolerated, and effective, with most patients achieving complete histological clearance of target lesions after treatment. The study involved eleven patients receiving seven topical applications over eight weeks. CEO Ofer Gonen highlighted the significant market potential for non-surgical BCC treatments. Final data is expected in the second half of 2022, further validating MW005's clinical efficacy.
MediWound Ltd. (Nasdaq: MDWD) announced an upcoming oral presentation at the Advanced Wound Care Summit on July 13-14, 2022, in Boston, MA. Dr. Robert Snyder will present an analysis titled “Market Landscape Analysis & EscharEx Market Potential” at 3:00 pm ET on July 13. The presentation will cover the wound care market and the potential of EscharEx, a therapy for chronic wound debridement currently in advanced clinical development. EscharEx has shown safety and efficacy in Phase 2 trials, and a meeting with the FDA is targeted for the second half of 2022.
MediWound Ltd. (Nasdaq: MDWD) announced positive results from a Phase 2 study of EscharEx, a biotherapeutic solution for debridement in venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). The study found that 70% of patients achieved complete debridement within up to 8 applications, with an average of 3.9 applications required. A significant reduction of 35% in wound size and effective biofilm disruption were noted. EscharEx was well-tolerated with ongoing biomarker analysis, underscoring its potential as a non-surgical treatment option.
MediWound Ltd. (Nasdaq: MDWD) will host an in-person Key Opinion Leader (KOL) breakfast meeting on EscharEx on July 12, 2022, at the St. Regis Hotel, New York City. Starting at 8:00 AM ET, the event will feature presentations from leading experts discussing wound debridement practices and EscharEx's clinical study results. CEO Ofer Gonen will provide a company update, followed by a Q&A session. The event will be webcast for those unable to attend in person. EscharEx is aimed at treating chronic wounds, showcasing MediWound's commitment to innovative wound care solutions.
MediWound Ltd. (Nasdaq: MDWD) has appointed Tzvi Palash as Chief Operating Officer (COO), effective June 30, 2022. Palash brings over 35 years of operational experience from prominent pharmaceutical companies. His previous roles include COO at Enlivex and Gamida Cell, where he oversaw critical BLA submissions. His expertise will support MediWound's development of EscharEx and the resubmission of the NexoBrid BLA. NexoBrid is a bromelain-based product for burn care marketed in the EU and at the registration stage in the U.S., backed by BARDA.
MediWound Ltd. (Nasdaq: MDWD) has appointed Ofer Gonen as its new Chief Executive Officer, effective June 30, 2022, succeeding Sharon Malka, who will transition to the Board of Directors. Gonen brings over 20 years of experience in life sciences and business development, previously serving as CEO of Clal Biotechnology Industries, MediWound's largest shareholder. The leadership change aims to position the company for long-term growth and enhance its capabilities in treating burns and wound care.
MediWound Ltd. (NASDAQ: MDWD) announced its Q1 2022 financial results, reporting revenues of $4.4 million, a 24% decline from $5.8 million in Q1 2021. The company faced a 56% drop in product revenue, primarily due to decreased emergency stockpile procurement by BARDA. Despite a net loss of $3.6 million or $0.12 per share, MediWound highlighted the positive results from its U.S. Phase 2 trial of EscharEx®, achieving primary and secondary endpoints with no safety issues. The company has raised $10 million through equity offerings and is on track for NexoBrid BLA resubmission by mid-year.
MediWound Ltd. (Nasdaq: MDWD) has announced positive results from its U.S. Phase 2 clinical study of EscharEx® for treating venous leg ulcers (VLUs). The study met its primary and key secondary endpoints with statistically significant improvements, including a 63% complete debridement rate in 14 days versus 30% for the control. EscharEx demonstrated a median time to complete debridement of 9 days compared to 59 days for standard care. The FDA meeting is anticipated in the second half of 2022 to discuss advancing to Phase 3 trials. No safety issues were observed, reinforcing EscharEx's therapeutic potential.
MediWound Ltd. (Nasdaq: MDWD) will announce its first-quarter financial results on May 17, 2022. The release will be followed by a conference call at 8:30 AM ET for management to discuss these results and provide corporate updates. MediWound specializes in bio-therapeutic solutions for tissue repair, notably its product NexoBrid for thermal burns, which has received support from BARDA. The company is also developing EscharEx for chronic wounds and MW005 for non-melanoma skin cancers. The webcast will be accessible for 90 days following the call.
FAQ
What is the current stock price of MediWound Ltd. (MDWD)?
What is the market cap of MediWound Ltd. (MDWD)?
What is MediWound Ltd.'s core business?
What is NexoBrid®?
What are the benefits of EscharEx®?
Who are MediWound's industry partners?
What recent achievements has MediWound accomplished?
What is the financial condition of MediWound Ltd.?
What are MediWound's future plans?
How does NexoBrid® work?
What makes MediWound's enzymatic technology unique?
Where can I find more information about MediWound Ltd.?
